Head-to-head · Value Score
Vitara RX vs myRocky
Two GLP-1 deals, scored on the same six factors. Vitara RX lands a Value Score of 91, myRocky a 37. Here's who gives you the honest lower price — and where each one bites back.
Vitara RX
#4 · Grade A · Best Value
Est. first month
$99/mo
Save ~93% vs brand-namemyRocky
#380 · Grade C · Watch List
Est. first month
From $1,409/mo (2 mg dose, brand-name)
The verdict
Vitara RX takes it on Value Score, 91 to 37 — an est. $99/mo first month, with no teaser step-up baked in. myRocky isn't out of it: Shoppers who want brand-name-only GLP-1s without insurance in 42 states.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | Vitara RX | myRocky |
|---|---|---|
| Value Score | 91 (A) | 37 (C) |
| Est. first month | $99/mo | From $1,409/mo (2 mg dose, brand-name) |
| Save vs brand-name | ~93% | — |
| Semaglutide | $99/mo | Not disclosed |
| Tirzepatide | $149/mo | Not disclosed |
| Both molecules | Yes | No |
| Pricing | Flat — no step-up | Watch |
| Coverage | 49 states | Coverage not published |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
Vitara RX
VitaraRx is a direct-to-consumer telehealth marketplace offering compounded semaglutide and tirzepatide at flat per-drug pricing across all doses — no membership or hidden fees.
Why it's a deal
- Among the lowest flat pricing in the market — $99/mo semaglutide and $149/mo tirzepatide, all doses same price
- Names its 503A pharmacy partner (Manifest Pharmacy, Greer SC) — strong supply-chain transparency
- LegitScript Certified
- Publishes the FDA compounded-medication disclaimer
- Covers 49 states with an explicit state list, not vague "most states" language
The fine print
- No corporate legal entity disclosed — only the trade name "VitaraRx"
- No named medical director — all clinical decisions made by independent providers (marketplace model)
- All sales final — no medication returns
- Per-vial mg quantity isn't clearly disclosed, making price comparisons harder
- Doesn't ship to Alaska
myRocky
myRocky is a Canadian-incorporated multi-product telehealth platform (Rocky Health Inc., Ontario) that markets brand-name GLP-1s — Ozempic, Mounjaro, and Wegovy — to US patients, with no compounded products.
Why it's a deal
- Brand-name FDA-approved GLP-1s (Ozempic, Mounjaro, Wegovy) on one platform — no compounded-product risk
- LegitScript Approved
- 42-state coverage with an 8-state expansion roadmap published
- Multi-product platform for patients managing GLP-1 plus sexual health, hair loss, or mental health on one subscription
The fine print
- Expensive stacked fees: $99 consult + $99/mo program fee + ~$1,409/mo medication = ~$1,508/mo
- Canadian incorporation (Rocky Health Inc., Mississauga, ON) — verify your state's prescriber holds an active US license
- Listed pharmacy is a Canadian community pharmacy; US-fulfillment supply chain not transparent
- Brand-only — no compounded option for cost-sensitive patients
- $1,409/mo Ozempic is near retail; compare NovoCare ($349/mo Wegovy pen) or LillyDirect ($449–$699/mo Zepbound)
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores Vitara RX is ranked on the Vitara RX alternatives board, and the same list for the other side is on alternatives to myRocky.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.